EDAP Schedules Webcast and Conference Call for Second Quarter 2013 Results

EDAP Schedules Webcast and Conference Call for Second Quarter 2013 Results

LYON, France, Aug. 13, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the
global leader in therapeutic ultrasound, announced today details relating to
its second quarter 2013 results announcement, which will take place on
Wednesday, August 28, 2013, before the opening of the market.

EDAP will hold a conference call on Wednesday, August 28, 2013 at 8:30 a.m.
EDT to discuss the results. The dial-in numbers are 1-877-300-8521 for
domestic callers and 1-412-317-6026 for international callers. The conference
ID number for both is 10032218. A live webcast of the conference call will be
available online from the investor relations page of the Company's corporate
website at www.edap-tms.com.

After the live webcast, the call will remain available on EDAP's website,
www.edap-tms.com, through September 25, 2013. In addition, a telephonic
replay of the call will be available until September 4, 2013. The replay
dial-in numbers are 1-877-870-5176 for domestic callers and 1-858-384-5517 for
international callers.Please use event passcode 10032218.

About EDAP TMS SA

EDAP TMS SA markets today Ablatherm® for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a
minimally invasive and effective treatment option with a low occurrence of
side effects. Ablatherm-HIFU is generally recommended for patients with
localized prostate cancer (stages T1-T2) who are not candidates for surgery or
who prefer an alternative option, or for patients who failed radiotherapy
treatment. Ablatherm-HIFU is approved and commercialized in Europe as a
treatment for prostate cancer and is currently under regulatory review in the
U.S. following submission of the Pre-Market Approval Application in February
2013 after the completion ofa multi-center U.S. Phase II/III clinical trial
under an Investigational Device Exemption (IDE) granted by the FDA. The
Company also develops its HIFU technology for the potential treatment of
certain other types of tumors. EDAP TMS SA also produces and commercializes
medical equipment (the Sonolith® range) for treatment of urinary tract stones
using extra-corporeal shockwave lithotripsy (ESWL). For more information on
the Company, please visit http://www.edap-tms.com, and
http://www.hifu-planet.com.

Forward-Looking Statements

In addition to historical information, this press release may contain
forward-looking statements that involve risks and uncertainties. Such
statements are based on management's current expectations and are subject to a
number of uncertainties, including the uncertainties of the regulatory
process, and risks that could cause actual results to differ materially from
those described in these forward-looking statements. Factors that may cause
such a difference include, but are not limited to, those described in the
Company's filings with the Securities and Exchange Commission and in
particular, in the sections "Cautionary Statement on Forward-Looking
Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Ablatherm-HIFU treatment is in clinical trials, but not FDA-approved or
marketed in the United States.

CONTACT: Blandine Confort
         Investor Relations / Legal Affairs
         EDAP TMS SA
         +33 4 72 15 31 72
         bconfort@edap-tms.com
        
         Investors:
         Stephanie Carrington
         The Ruth Group
         646-536-7017
         scarrington@theruthgroup.com
 
Press spacebar to pause and continue. Press esc to stop.